🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Impressive talk by Mangiante on tissue ecology from ER+ breast cancer. #CRCL25 CRCL nature.com/articles/s4158…

Out today in JTO & JTO CRR our case report detailing discordant IO response in biphasic diffuse pleural mesothelioma with identification of BRAF V600E and durable response to BRAF/MEK TKI. Highlights importance of NGS in this rare malignancy. jtocrr.org/article/S2666-…

Resistance to BRAFi + MEKi in #BRAF V600E melanoma patients is driven by activation of focal adhesion signaling. Avutometinib (RAF-MEK clamp) in combination with FAKi reverts resistance to BRAFi plus MEKi or to immunotherapy. dlvr.it/TJFQ3d

#ELCC2025 is not yet over ! Great presentation by Sandra Ortiz-Cuaran on resistance to targeted therapies inn#NSCLC covering the heterogeneity of mechanisms. Key is probably to decipher the early drug tolerance state.

Proud to have had the chance to communicate on these collaborative networks at #ELCC. Looking forward to advancing basic and translationam research on #BRAF-mutant #NSCLC and other oncogene-driven #NSCLC.

Superb progress for our #BRAF #lungcancer patients, but there's still a long way to go...requiring collaborative work like that underway with the #BOLERO consortium Sandra Ortiz-Cuaran Julien Mazieres, so don't hesitate to join us!

#BRAF #BOLERO #Lungcancer

Dr. Christine Lovly, MD, PhD, FASCO and I discuss #AACR25 highlights on the latest episode of the IASLC podcast, Lung Cancer Considered. Several important clinical updates for lung cancer management from AACR including zongertinib and aumolertinib updates. iaslc.org/iaslc-news/lun…

Response and Resistance to #RAS Inhibition in Cancer. Cancer Discovery aacrjournals.org/cancerdiscover…

Hi everyone - my previous account Biagio Ricciuti, MD PhD was compromised and is no longer under my control. This is my new official profile Biagio Ricciuti, MD, PhD. I’d be grateful if you could kindly help spread the word. OncoAlert Dana-Farber Dana-Farber News

#BRAF V600E detection and effective BRAF/MEKi treatment in a pure epithelioid #mesothelioma upon progression on ICI (biphasic MPM at baseline). #LCSM jtocrr.org/article/S2666-…

Do not miss the 10th CRCL Thematic day ! Great speaker lineup to discuss whether and how the #environment shapes cancer risk over time. 🗓 June 6th, 2025 📢 Virtual or in-person ✅️ Free registration (link below) eventbrite.com/e/10th-crcl-th…

Thrilled to share this exciting study ⁦Nature Medicine⁩. Largest integrative analysis of #sotorasib efficacy biomarkers to date. Grateful to all co- investigators and the Amgen team for their hard work and most of all to our patients. ⁦MD Anderson Cancer Center⁩ #KRAS #NSCLC

Global trends in lung cancer reported Lung Cancer Journal. Notable for general increase in lung cancer incidence and mortality in women, esp France (incidence) and Norway (mortality). Increases noted in some countries despite decrease in tobacco use (Japan). lungcancerjournal.info/article/S0169-…

#JustOut: Updated ESMO recommendations for systemic treatment of oncogene-addicted metastatic #NSCLC. 🔴 There is still a lack of targeted or more effective therapies for #BRAFnonV600E NSCLC pts, who represent 2/3rds of #BRAF mut NSCLC. BrafBombers ow.ly/9Pue50WbqiV

SCLC transformation from EGFR+ NSCLC, outcomes & tx? ESMO Open: - 25pts: CT (n=12), CT+EGFR-TKI (n=5), CT+ICI (n=6), CT+ICI+TKI (n=1) - mPFS 2m; mOS 9m, similar across tx - mOS if transf >12m v <12m (31m vs 8m, p<0.001) Chiara CATANIA OncoAlert #LCSM esmoopen.com/article/S2059-…